These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37882631)

  • 1. Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism.
    Cosenza-Contreras M; Schäfer A; Sing J; Cook L; Stillger MN; Chen CY; Villacorta Hidalgo J; Pinter N; Meyer L; Werner T; Bug D; Haberl Z; Kübeck O; Zhao K; Stei S; Gafencu AV; Ionita R; Brehar FM; Ferrer-Lozano J; Ribas G; Cerdá-Alberich L; Martí-Bonmatí L; Nimsky C; Van Straaten A; Biniossek ML; Föll M; Cabezas-Wallscheid N; Büscher J; Röst H; Arnoux A; Bartsch JW; Schilling O
    Neuro Oncol; 2024 Mar; 26(3):488-502. PubMed ID: 37882631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
    Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
    Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated microenvironment-associated genomic profiles identify LRRC15 mediating recurrent glioblastoma-associated macrophages infiltration.
    Tang H; Liu W; Xu Z; Zhao J; Wang W; Yu Z; Wei M
    J Cell Mol Med; 2021 Jun; 25(12):5534-5546. PubMed ID: 33960636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers.
    Tatari N; Khan S; Livingstone J; Zhai K; Mckenna D; Ignatchenko V; Chokshi C; Gwynne WD; Singh M; Revill S; Mikolajewicz N; Zhu C; Chan J; Hawkins C; Lu JQ; Provias JP; Ask K; Morrissy S; Brown S; Weiss T; Weller M; Han H; Greenspoon JN; Moffat J; Venugopal C; Boutros PC; Singh SK; Kislinger T
    Acta Neuropathol; 2022 Dec; 144(6):1127-1142. PubMed ID: 36178522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.
    Indraccolo S; Lombardi G; Fassan M; Pasqualini L; Giunco S; Marcato R; Gasparini A; Candiotto C; Nalio S; Fiduccia P; Fanelli GN; Pambuku A; Della Puppa A; D'Avella D; Bonaldi L; Gardiman MP; Bertorelle R; De Rossi A; Zagonel V
    Clin Cancer Res; 2019 Mar; 25(6):1828-1837. PubMed ID: 30514778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decoding key cell sub-populations and molecular alterations in glioblastoma at recurrence by single-cell analysis.
    Wang X; Sun Q; Wang W; Liu B; Gu Y; Chen L
    Acta Neuropathol Commun; 2023 Jul; 11(1):125. PubMed ID: 37525259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative analysis of transcriptome and proteome profiles in primary and recurrent glioblastoma.
    Zhang J; Wang G; Yan B; Yang G; Yang Q; Hu Y; Guo J; Zhao N; Wang L; Wang H
    Proteomics Clin Appl; 2024 May; 18(3):e2200085. PubMed ID: 38037768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Acid Ceramidase Inhibits Glioblastoma Cell Migration through Decreased AKT Signaling.
    Hawkins CC; Jones AB; Gordon ER; Williford SE; Harsh Y; Ziebro JK; Landis CJ; Gc S; Crossman DK; Cooper SJ; Ramanadham S; Doan N; Hjelmeland AB
    Cells; 2022 Jun; 11(12):. PubMed ID: 35741006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.
    Qazi MA; Vora P; Venugopal C; Adams J; Singh M; Hu A; Gorelik M; Subapanditha MK; Savage N; Yang J; Chokshi C; London M; Gont A; Bobrowski D; Grinshtein N; Brown KR; Murty NK; Nilvebrant J; Kaplan D; Moffat J; Sidhu S; Singh SK
    Cancer Res; 2018 Sep; 78(17):5023-5037. PubMed ID: 29945963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma.
    Zhang L; Jiang Y; Zhang G; Wei S
    Front Immunol; 2023; 14():1238233. PubMed ID: 37731483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease.
    Mallawaaratchy DM; Hallal S; Russell B; Ly L; Ebrahimkhani S; Wei H; Christopherson RI; Buckland ME; Kaufman KL
    J Neurooncol; 2017 Jan; 131(2):233-244. PubMed ID: 27770278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions.
    Buehler M; Yi X; Ge W; Blattmann P; Rushing E; Reifenberger G; Felsberg J; Yeh C; Corn JE; Regli L; Zhang J; Cloos A; Ravi VM; Wiestler B; Heiland DH; Aebersold R; Weller M; Guo T; Weiss T
    Neuro Oncol; 2023 Feb; 25(2):290-302. PubMed ID: 35802605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration.
    Uneda A; Kurozumi K; Fujimura A; Fujii K; Ishida J; Shimazu Y; Otani Y; Tomita Y; Hattori Y; Matsumoto Y; Tsuboi N; Makino K; Hirano S; Kamiya A; Date I
    Acta Neuropathol Commun; 2021 Feb; 9(1):29. PubMed ID: 33618763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Heterogeneity of Tumour-Associated Macrophages Contributes to the Recurrence and Outcomes of Glioblastoma Patients.
    Xuan Z; Fang L; Zhang G; Zhang X; Jiang J; Wang K; Huang P
    J Mol Neurosci; 2023 Jan; 73(1):1-14. PubMed ID: 36542317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
    Syafruddin SE; Nazarie WFWM; Moidu NA; Soon BH; Mohtar MA
    BMC Cancer; 2021 Jul; 21(1):850. PubMed ID: 34301218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
    Liau LM; Ashkan K; Brem S; Campian JL; Trusheim JE; Iwamoto FM; Tran DD; Ansstas G; Cobbs CS; Heth JA; Salacz ME; D'Andre S; Aiken RD; Moshel YA; Nam JY; Pillainayagam CP; Wagner SA; Walter KA; Chaudhary R; Goldlust SA; Lee IY; Bota DA; Elinzano H; Grewal J; Lillehei K; Mikkelsen T; Walbert T; Abram S; Brenner AJ; Ewend MG; Khagi S; Lovick DS; Portnow J; Kim L; Loudon WG; Martinez NL; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Giglio P; Gligich O; Krex D; Lindhorst SM; Lutzky J; Meisel HJ; Nadji-Ohl M; Sanchin L; Sloan A; Taylor LP; Wu JK; Dunbar EM; Etame AB; Kesari S; Mathieu D; Piccioni DE; Baskin DS; Lacroix M; May SA; New PZ; Pluard TJ; Toms SA; Tse V; Peak S; Villano JL; Battiste JD; Mulholland PJ; Pearlman ML; Petrecca K; Schulder M; Prins RM; Boynton AL; Bosch ML
    JAMA Oncol; 2023 Jan; 9(1):112-121. PubMed ID: 36394838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular Matrix Proteome Remodeling in Human Glioblastoma and Medulloblastoma.
    Trombetta-Lima M; Rosa-Fernandes L; Angeli CB; Moretti IF; Franco YM; Mousessian AS; Wakamatsu A; Lerario AM; Oba-Shinjo SM; Pasqualucci CA; Marie SKN; Palmisano G
    J Proteome Res; 2021 Oct; 20(10):4693-4707. PubMed ID: 34533964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.
    Anghileri E; Di Ianni N; Paterra R; Langella T; Zhao J; Eoli M; Patanè M; Pollo B; Cuccarini V; Iavarone A; Rabadan R; Finocchiaro G; Pellegatta S
    Cancer Immunol Immunother; 2021 Mar; 70(3):831-842. PubMed ID: 33140187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Stem Cell-Associated Immune Microenvironment in Recurrent Glioblastomas.
    Murota Y; Tabu K; Taga T
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma.
    Zhao B; Wu J; Li H; Wang Y; Wang Y; Xing H; Wang Y; Ma W
    Cell Commun Signal; 2023 Apr; 21(1):74. PubMed ID: 37046332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.